Sesen Bio — Q1 2021 Earnings Presentation
76 slides from Sesen Bio's earnings presentation, May 10, 2021
Slide 1: 1Q 2021 Business Update
NASDAQ: SESN 1Q 2021 Business Update May 10, 2021
Slide 2: Forward-Looking Statements
2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical dev
Slide 3: May 2021 Business Update
3 MAY 2021 BUSINESS UPDATE 1. Vicineum has the potential to improve patient outcomes while reducing overall healthcare costs 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Vicineum has the potential to be best- in-class with projected global peak revenue
Slide 4: Bladder cancer patient journey
4 BLOOD IN URINE Begin tests Cytology DIAGNOSIS BCG Testing Urologist visit UROLOGIST MAKES TREATMENT CHOICE Bladder removal See blood in urine; try different antibiotic See PCP; therapeutic trial of antibiotics prescribed BCG has failed TURBT Cystoscopy Bladder MRI CT Scan BCG Testing BCG again BCG
Slide 5: Positive Progress in Key Regions Provides a Clear Regulatory Path Forward
5 4Q 20 1Q 21 2Q 21 3Q 21 4Q 21 2Q 221Q 22 1. Regulatory submission expected in 2022, potential approval in 2023; 2. Key markets include Kingdom of Saudi Arabia, Jordan, Morocco and Egypt BLA: Biologics License Application; MAA: Marketing Authorization Application; HTA: Health Technology Assessment;
Slide 6: Brand Strategy
6 Brand Strategy: To position Vicineum as the “Best in Class” which improves patient outcomes while reducing overall healthcare costs** Brand Goal: US market leadership in NMIBC in late-2022 Brand Forecast: Peak global sales of $1B - $3B *Conditional approval of proprietary brand name; final approva
Slide 7: Go-to-Market Strategy
7 Primary Targets (~2,000) National KOLs (~60) Regional KOLs (~240) • Engage key leaders • Ensure high awareness of clinical data Field Sales Representatives Medical Science Liaisons Go-to-Market Strategy Practices (~350) Reimbursement Support Key Objectives • Provide concierge patient management su
Slide 8: High Prescribing Urologists Prefer Vicineum Profile
8 5.4 8.2 8.2 8.6 5.2 6.2 3.4 5.8 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Efficacy Safety Ease of integration Interest in use of product A ve ra ge R at in g Vicineum Profile Keytruda Profile Source: Emerging treatment in-depth interviews (IDIs) with high BCG-treating Urologists, 1Q 2020, N=34
Slide 9: Manufacturing and supply chain partners
9 Our mission is to save and improve the lives of patients with cancer Current Suppliers Future Additional Supplier* Vicineum Drug Substance manufacturer • 7 commercial products launched from site where Vicineum is manufactured; 3 produced via E. coli and 2 oncology products • 30+ years manufacturin
Slide 10: Vicineum manufacturing process
10 Cell Bank 2000 L E. coli Production Bioreactor 5: Q-Sepharose HP 5 Column Purification Shake flask Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) DP Fill Finish (7 mL @ 5mg/mL)1: Q-Sepharose FF 3: Q-Sepharose HP 4: CHT2: Ni2+ IMAC BDS
Slide 11: Reliable and Inexpensive Manufacturing Process
11 • Vicineum is manufactured using a robust, industry-standard microbial expression system • The manufacturing process is highly reliable, reducing the risk of supply shortages • The manufacturing process is inexpensive, leading to a relatively low cost-of-goods • For manufacturing, we have world-c
Slide 12: Strengthening the Balance Sheet while Minimizing Dilution
12 YE 2020 Dec. 31, 2020 1Q 2021 Mar. 31, 2021 % Change Cash, cash equivalents, and restricted cash $55M $110M +100% Stock price $1.35 $2.60 +93% Market cap $190M $447M +135% • No outstanding debt • Strengthened the balance sheet via prudent use of the ATM facility Financial Highlights Strengthening
Slide 13: Sesen Quarterly Cash Balances
13 $M $9.6 $13.9 $11.1 $18.5 $4.8 $18.2 $24.5 $73.1 $37.7 $42.0 $55.4 $110.0 0 20 40 60 80 100 120 2Q 20 3Q 20 4Q 20 1Q 21 Cash used in Operations Cash Raised Ending cash and cash equivalents Note: Ending cash includes restricted cash Sesen Quarterly Cash Balances Steadily Building Cash Balance to S
Slide 14: Sesen Bio May 2021 Highlights
14 SESEN B IO MAY 2021 HIGHLIGHTS 1. Vicineum has the potential to improve patient outcomes while reducing overall healthcare costs 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Vicineum has the potential to be best- in-class with projected global peak r
Slide 15: Thank You
THANK YOU
Slide 16: Talented and Experienced Leadership Team
16 Thomas Cannell, DVM President, CEO and Director Glen MacDonald, Ph.D. Chief Technology Officer Mark Sullivan General Counsel and Corporate Secretary Erin Clark Vice President, Corporate Strategy and Investor Relations Monica Forbes Chief Financial Officer Omar Rifi Vice President, Business Develo
Slide 17: Appendix - Table of Contents
17For investor purposes only, not intended for promotional purposes Appendix - Table of Contents Section Slide number Unmet Medical Need 18-22 Dual Mechanism of Action 23-26 Regulatory 27-30 Clinical Data 31-51 Commercial Opportunity 52-71 Manufacturing & Supply Chain 72-74 Intellectual Property 75-
Slide 18: Unmet Medical Need
18 Unmet Medical Need Appendix
Slide 19: Significant Unmet Medical Need in NMIBC
19 BCG ~440,000 new cases each year globally1 is complicating patient care Significant Unmet Medical Need in NMIBC 1Bray F et al. CA Cancer J Clin, 2018. 2Anastasiadis et al. Therapeutic Advances in Urology, 2012. 3Siegel et al. CA Cancer J Clin, 2019. 4Svatek RS, et al. Eur Oncol. 2014. 5Office of
Slide 20: Significant Unmet Need for Patients with Bladder Cancer
20 There is a Significant Unmet Need for Patients with Bladder Cancer with Limited Treatment Options Available Common Types of Cancer Estimated New Cases 2020 Estimated Deaths 2020 1. Breast Cancer (Female) 276,480 42,690 2. Lung and Bronchus Cancer 228,820 135,720 3. Prostate Cancer 191,930 33,330
Slide 21: Vicineum is bladder-sparing by delaying or avoiding cystectomy
21 Our Phase III data suggests Vicineum is bladder-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery Self-controlled storage organ in the body Holds urine for release so the body is not exposed to harm
Slide 22: NMIBC Therapeutics Plagued by Manufacturing Issues
22 NMIBC Therapeutics Have Been Plagued by Manufacturing Issues 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production of BCG Connaught strain during facility renovations Merck announces shortages of BCG Tice strain Sanofi discontinues all global production of BCG Connaught strain M
Slide 23: Dual Mechanism of Action
23 Dual Mechanism of Action Appendix
Slide 24: Highly Differentiated Dual Mechanism of Action
24 Vicineum has a Highly Differentiated Dual Mechanism of Action (MoA) An Important Advancement in the Category of Precision Oncology • Fusion protein consisting of an antibody fragment and a cytotoxic payload • Small size facilitates tumor penetration and greater drug delivery • Selectively targets
Slide 25: Vicineum has a Highly Differentiated Mechanism of Action
25 T cells recognize neoantigen and kill cancer cells T cell proliferation DAMPs Neoantigen release Vicineum causes immunogenic cell death by triggering damage-associated molecular patterns (DAMPs) Vicineum selectively targets EpCAM on cancer cells while generally leaving healthy cells alone Vicineu
Slide 26: Evidence of activation of patients' immune systems
26 A f t e r 4 w k s o n t r e a t m e n t P r e - t r e a t m e n t PAT I E N T A : PAT I E N T B : Injected Tumor Injected Tumor Non-Injected Tumor Pre-clinical and Phase I Trial in SCCHN shows evidence of activation of patients’ immune systems Clinical Evidence (as seen in Phase I) Pre-Clinical E
Slide 27: Regulatory
27 Regulatory Appendix
Slide 28: FDA guidance for BCG-unresponsive NMIBC
28Source: FDA Guidance: BCG-Unresponsive Non-muscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry, February 2018. CRR, Complete Response Rate; DoR, Duration of Response; BCG, bacillus Calmette-Guérin; WHO, World Health Organization. • Conduct nonclinical
Slide 29: BLA Finalized and Submitted to the FDA
29 BLA Finalized and Submitted to the FDA on December 18, 2020 Positive Analytical Comparability Data Led to BLA Completion General corporate information Patent information and exclusivity Waivers Draft Label Risk management plan Draft carton and container labels 24 Non-clinical studie
Slide 30: Completion of Vicineum BLA Submission in December 2020
30 Completion of Vicineum BLA Submission in December 2020 Sources: FDA applications for oncology products 2006 – 2015. Thomas D.W. et al., Clinical development success rates 2006-2015. 2016. Bio, BioMedTracker and Amplion. Phase Probability of Approval Products at end of Phase I 5% Products at end o
Slide 31: Clinical Data
31 Clinical Data Appendix Note: the clinical data shown are based on the data submitted in the BLA on December 18, 2020 and is current under review by the FDA. Final numbers are pending.
Slide 32: Strong benefit-risk profile in Phase III Trial
32 : Vicineum demonstrates a strong benefit-risk profile in our Phase III Trial Benefit Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkpoint inhibitors No dose or age-related increase in AEs Intrav
Slide 33: Phase III Trial: Patient Demographics
33 Phase III Trial: Patient Demographics TURBT: transurethral resection of bladder tumor Data are as of May 29, 2019 data cut Note: the clinical data shown are based on the data submitted in the BLA on December 18, 2020 and are currently under review by the FDA. Final numbers are pending. CHARACTERI
Slide 34: Compelling Clinical Data Set
34 Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) Primary Endpoint CIS patients Defined as the proportion of patients who show no evidence of high-risk disease, or disease progression (e.g., T2 or more advanced disease). • 40% CRR at 3 months • Lo
Slide 35: Complete and Partial Response
35 Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response Start of Treatment with Vicineum 3-Month Response 40% of patients had a complete response 43% of patients had a partial response 17% of patients had no response *Note: Data are from P
Slide 36: Duration of Response
36 Duration of response: defined as the time of complete response to treatment failure. *Not Estimable, the upper bound for the 95% confidence interval has not reached the median. **Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Median duration of response for th
Slide 37: Duration of Response by BCG exposure
37 Duration of Response: Vicineum is generally more efficacious in CIS patients treated with less BCG Duration of response: defined as the time of complete response to treatment failure. *Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. The clinical data shown are
Slide 38: Longer complete response, higher probability of remaining cancer-free
38 Duration of response: defined as the time from complete response to treatment failure. *Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Note: the clinical data shown are based on the data submitted in the BLA on December 18, 2020 and are currently under review by the
Slide 39: Time to Disease Recurrence
39 Time to Disease Recurrence: Time to Disease Recurrence: 50% of high-risk papillary patients who were treated with Vicineum are disease-free at 1 year Time to disease recurrence: defined as the time from the date of the first dose of study treatment to treatment failure. Median time to disease rec
Slide 40: Time to Cystectomy data vs. currently available agents
40 2018 FDA Guidance: The goal of therapy in patients with BCG-unresponsive NMIBC is to avoid cystectomy. % o f P at ie nt s C ys te ct o m y- Fr ee Median 3 6 9 12 15 18 21 240 27 30 33 Time from start of treatment (months) KM Estimate Censored 95% CI X Legend: No patient on treatment progressed to
Slide 41: Time to Cystectomy in responders
41 Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment Time to cystectomy: defined as the time from the date of first dose of study treatment to surgical bladder removal. Data consist of patients from all cohorts (n=133). Note: the cli
Slide 42: Overall Survival
42 Overall Survival 1- and 2-year survival rates of patients on trial are comparable to those of the general population of similar age and gender demographics (predominantly male in their 70s) 1U.S. Social Security Administration Actuarial Life Table (https://www.ssa.gov/oact/STATS/table4c6.html), B
Slide 43: Additional Vicineum Clinical Data
43 Additional Vicineum Clinical Data Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3-months 40% (26%-56%) 40% (30%- 51%) 6-months 27% (15%-42%) 28% (19%-39%) 9-months 18% (8%-32%) 21%
Slide 44: Evaluable Patient Data Tables for Carcinoma in situ
44 Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3-months n=82 39% (28%-50%) 6-months n=82 26% (17%-36%) 9-months n=82 20% (12%-30%) 12-months n=82 1
Slide 45: Recurrence-free Rate in papillary patients
45 Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence-free (RF) Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3-months n=38 71% (54%-85%) 6-months n=38 58% (41%-74%) 9-months n=38 45% (29%-62%) 12-month
Slide 46: Safety and Tolerability
46 Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Category Phase II Patients (%) Phase III Patients (%) Any AE 43 (94%) 117 (88%) Grade 3-5 AEs 9 (20%) 29 (22%) Treatment-related AEs 30 (65%) 66 (50%) Treatment-related Grade 3-5
Slide 47: No age-related increase in adverse events
47 M ea n A E s/ pa tie nt 0 2 4 6 8 10 Safety and Tolerability: No age-related increase in adverse events in our Phase III trial Note: Data consist of patients from all cohorts (n=133). Mean AEs for all patients: 8.1 (range 0-54), Mean treatment-related AEs for all patients: 2.2 (range 0-51). The c
Slide 48: Confidence interval above FDA success criterion
48 Vicineum confidence interval above FDA success criterion based upon complete response of other agents in patients with Carcinoma in situ Please use caution when drawing comparisons across different clinical trials 2Data are as of May 29, 2019 data cut from the Phase III VISTA trial. The clinical
Slide 49: Head and Neck Cancer: Difficult-to-Treat
HEAD AND NECK CANCER: Difficult-to-Treat & Dominated by Primary Tumor • Head and neck cancer affects >650,000 people worldwide; ~350,000 deaths each year1 • 90% are squamous cell carcinomas of the head and neck (SCCHN)1 - Two-thirds diagnosed with advanced disease and severe prognosis • High risk of
Slide 50: Vicineum Monotherapy Studies in Late-stage SCCHN
50 PHASE 1 TRIALS ASSESSING DAILY AND WEEKLY DOSES SUGGEST IMMUNE-DRIVEN RESPONSE • Anti-tumor activity of 43% on daily dose; 62% on weekly dose • Observed regression or complete resolution of non- injected tumors • 207 days mean overall survival for EpCAM-positive patients vs. 125 days for EpCAM-ne
Slide 51: Partnership Opportunity with LUMC
51 Partnership Opportunity with LUMC Further Supports the Targeting Specificity of Vicineum Gastric Cancer Colorectal Cancer Esophageal Cancer LUMC = Leiden University Medical Center, the university hospital affiliated with Leiden University. LUMC is a modern university medical center for research,
Slide 52: Commercial Opportunity
52 Commercial Opportunity Appendix For investor purposes only, not intended for promotional purposes
Slide 53: Virtuous Cycle
53 Virtuous Cycle High possibility that all three key segments are advocates & take action Sources: Sesen Bio internal market research: Patient Journey Insights, Blue Print qualitative study May 2018, n=24; Sesen Market Opportunity, Monitor Deloitte qualitative and quantitative (n=34) study October
Slide 54: Commercial Strategy Supports World-Class US Launch
54 • Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after approval and launch • Urologists who treat NMIBC indicate a preference for Vicineum vs. Keytruda • Highly concentrated US market of ~1,500 Urologists treating
Slide 55: Differentiated vs. branded agents in Urology
55 Brand Logo Differentiated vs. branded agents in Urology TM For investor purposes only, not intended for promotional purposes
Slide 56: Potential to Provide Continuity of Care
56 Treatment Protocol BCG Vicineum Checkpoint Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X Vicineum has the Potential to Provide Continuity of Care for Patients with NM
Slide 57: Clinical Data from Emerging Treatments for NMIBC
57 Vicineum Profile Registration Trial Keytruda Profile Registration Trial Key Patient Criteria • Failed BCG (5+2) • CIS +/-Ta/T1 • All comers • Failed BCG (5+2) • CIS +/-Ta/T1 • Ineligible or refuse cystectomy Efficacy N=89 N=102 Complete Response Rate At 3 Months At 12 Months At 18 Months 40% (CI:
Slide 58: Market Research Results
58 Market Research Results Reasons Urologists Prefer Vicineum Profile • Urologists strongly prefer to retain ownership of patient journey – High degree of reluctance to refer to Medical Oncologists – Fear of losing follow-up diagnostics with patient after treatment referral • Urologists perceive fav
Slide 59: Educating caregivers via digital and social channels
59 At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital • Paid search • Organic search • Videos • Banners • Website (branded or unbranded) Social • Facebook community groups •
Slide 60: Pricing and Reimbursement
60 Pricing and Reimbursement US Benchmarks Price Reference (Annual Cost) $200K $0K Sources: 1Center for Medicare and Medicaid Services (CMS) Average Selling Price (ASP) Price List as of 1Q 2020 (cms.gov). 2Payer Interviews, ClearView Analysis, n=10, March 2019. *Note: Payers cited a possibility of u
Slide 61: Favorable Cost-Effectiveness Profile (ICER)
61 Favorable Cost-Effectiveness Profile for Vicineum Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER) Overview: • ICER is the leading Health Technology Assessment body in the United States, and is an independent non-profit, research organization that
Slide 62: Competitor landscape in NMIBC
62 Checkpoint Inhibitors: Keytruda • Approved for NMIBC January 2020 • Reimbursed at $175,000/year with minimal payer restrictions Tecentriq • Awaiting Phase III enrollment • Phase II closed prematurely as it failed to meet futility endpoint • Withdrew label for advanced Urothelial Carcinoma indicat
Slide 63: Competitive Summary: BCG-Unresponsive NMIBC therapies
63 Competitive Summary: BCG-Unresponsive NMIBC therapies Report CR rate at discrete timepoints Patient failures taken off therapy Local and Central review of pathology BCG + N-803 BCG in combo with rIL-15 Vicineum Fusion Protein (Dual MOA) Keytruda Checkpoint Inhibitor Adstiladrin Gene Therapy Tre
Slide 64: Pipeline of Targeted Therapies
64 Pipeline of Targeted Therapies We Will Steadily Progress into Business Adjacencies Core BCG-unresponsive NMIBC Adjacent Less-than-adequate BCG Combo Therapy with CI First-line, high-risk NMIBC Transformational Head and Neck Cancer Imaging Agent VB6-845d (deBouganin) IL-6 Partnership W h er e to P
Slide 65: Sesen Bio OUS Strategy Overview
65 Sesen Bio OUS Strategy Overview • Vicineum is a product with potential for registration and reimbursement in multiple developed markets • OUS opportunity for Vicineum is 2-3 times larger than the US • Efficient process to manage strong, engaged relationships with key partners worldwide • Partner
Slide 66: Partnership Opportunity in China: Qilu
66 Partnership Opportunity in China: Qilu Pharmaceutical Profile • Top 10 Pharmaceutical Company in China with >$3B in annual revenue • Extensive clinical experience • 2nd largest clinical team in Chinese Big Pharma • Focused on biosimilar and innovative drugs, with nearly 40 years of clinical devel
Slide 67: Overview of Qilu License Agreement
67 Overview of Qilu License Agreement • Financial terms include significant sources of non-dilutive capital • Upfront payment of $12M in cash • Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to 12% royalties on net sales for at least 12 years • Qilu will be
Slide 68: Significant Milestones Achieved through Qilu Partnership
68 Significant Milestones Achieved through Qilu Pharmaceutical Partnership Overview of Key Progress • $12M upfront received on September 29, 2020 • Commercial manufacturing and global supply framework agreement signed on December 4, 2020 • Helps to ensure reliable global supply and creates opportuni
Slide 69: Key partnership with Hikma in MENA
69 Key partnership with leading partner in MENA Hikma Pharmaceuticals Profile • Multi-national pharma company specializing in the development and commercialization of a broad range of high-quality medicines across the US, MENA and Europe • Public company headquartered in London with a market cap of
Slide 70: Simulation Inputs: US Market
70 Simulation Inputs: US Market Estimated patients eligible for branded therapy1 (Annual high-risk NMIBC patients unresponsive to BCG) Lower Bound 7,800 patients Upper Bound 20,400 patients Estimated peak market share2 (Likely share of branded agents) Approximate year 1 doses received3 (Percent of p
Slide 71: Simulation Inputs: OUS Market
71 Simulation Inputs: OUS Market Sources: Ferlay. Intern. J. Canc. 2015; UN World Population Reports; SEER; GLOBOCAN; RedBook; Lauertaxe; Ameli; NICE; Vademecum; AIFA; NHI; CADTH; ANVISA; CBiP; Danish Medicines Agency; The Pharmaceutical Benefits Scheme; Saudi Food & Drug Authority; South African Me
Slide 72: Manufacturing & Supply Chain
72 Manufacturing & Supply Chain Appendix
Slide 73: Commercial Manufacturing Strategy Based on Demonstrating Comparability
73 Commercial Manufacturing Strategy Based on Demonstrating Comparability The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing • Assesses the purity, biological activity and general characteristics of Vicineum 2. Biophysical Characterization • Assesses the
Slide 74: Meaningful Progress on Demonstrating Comparability
74 Meaningful Progress on Demonstrating Comparability Indicates acceptance criteria met for batches used in clinical trials (Sesen) or technology transfer (FUJIFILM Diosynth Biotechnologies) Sesen FUJIFILM Diosynth Biotechnologies Test Phase III PPQ1 PPQ2 PPQ3 Appearance pH Identity
Slide 75: Intellectual Property
75 Intellectual Property Appendix
Slide 76: Vicineum Patent Life
76Note: Patent life assessment reflects independent analysis by Hogan Lovells US LLP. *Data exclusivity granted by FDA under the Biologics Price Competition and Innovation Act of 2009 (codified at 42 U.S.C. § 262(k)) Vicineum Patent Life Potential for 12 years of biologics marketing exclusivity from